Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer E Towne

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Journal of Leukocyte Biology|February 13, 2015
Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditionsCem Gabay, Jennifer E Towne
Immunity|August 22, 2019
A Role for IL-12 in IBD after All?Carrie N Arnold Greving, Jennifer E Towne
Immunological Reviews|December 17, 2017
Regulation and function of interleukin-36 cytokinesEsen Yonca Bassoy, Jennifer E Towne, Cem Gabay
Nature Immunology|February 2, 2019
Publisher Correction: Get the IL-17F outta here!Aisling O'Hara Hall, Jennifer E Towne, Scott E Plevy
Cytokine|June 9, 2022
Role of IL-36 cytokines in psoriasis and other inflammatory skin conditionsKacey L Sachen, Carrie N Arnold Greving, Jennifer E Towne
Cancer Research|February 2, 2011
Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastasesMichele W L Teng, Bianca von Scheidt, Helene Duret, et al.
The Journal of Biological Chemistry|January 22, 2004
Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKsJennifer E Towne, Kirsten E Garka, Blair R Renshaw, et al.
Trends in Immunology|January 8, 2013
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responsesMichelle A Lowes, Chris B Russell, David A Martin, et al.
The Journal of Investigative Dermatology|June 8, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsDavid A Martin, Jennifer E Towne, Gregory Kricorian, et al.
The Journal of Biological Chemistry|October 4, 2011
Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activityJennifer E Towne, Blair R Renshaw, Jason Douangpanya, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal of Leukocyte Biology|February 13, 2015
Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditionsCem Gabay, Jennifer E Towne
Immunity|August 22, 2019
A Role for IL-12 in IBD after All?Carrie N Arnold Greving, Jennifer E Towne
Immunological Reviews|December 17, 2017
Regulation and function of interleukin-36 cytokinesEsen Yonca Bassoy, Jennifer E Towne, Cem Gabay
Nature Immunology|February 2, 2019
Publisher Correction: Get the IL-17F outta here!Aisling O'Hara Hall, Jennifer E Towne, Scott E Plevy
Cytokine|June 9, 2022
Role of IL-36 cytokines in psoriasis and other inflammatory skin conditionsKacey L Sachen, Carrie N Arnold Greving, Jennifer E Towne
Cancer Research|February 2, 2011
Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastasesMichele W L Teng, Bianca von Scheidt, Helene Duret, et al.
The Journal of Biological Chemistry|January 22, 2004
Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKsJennifer E Towne, Kirsten E Garka, Blair R Renshaw, et al.
Trends in Immunology|January 8, 2013
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responsesMichelle A Lowes, Chris B Russell, David A Martin, et al.
The Journal of Investigative Dermatology|June 8, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsDavid A Martin, Jennifer E Towne, Gregory Kricorian, et al.
The Journal of Biological Chemistry|October 4, 2011
Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activityJennifer E Towne, Blair R Renshaw, Jason Douangpanya, et al.
Pageof 3